207 Poster Session 2 - Connective Tissue Oncology Society

Scientific Posters – Poster Session 2dian=72.9); p 4 pts), proportion of patients with moderate/severeworst pain at baseline shifting to no/mild worst pain, andchange in analgesic score on the Analgesic QuantificationAlgorithm (AQA) from baseline (0: no analgesics–7: strongopioids, > 600mg oral morphine equivalent/day).Results: Within the first week of receiving denosumab,31% (54 of 172) of patients reported a clinically meaningfulimprovement in pain. Starting at week 5, more than 50%of patients reported an improvement in pain at each visitthrough month 30. Among patients with moderate/severepain at baseline, more than 42% improved to no/mild painduring the same time period. Throughout the study, 22% orfewer patients had pain worsening (shifting from no/mildpain at baseline to moderate/severe pain). Up to 38% ofpatients decreased analgesic use from strong opioids (≥ 3pts) at baseline to no/low analgesic use (≤ 2 pts) at sometime on study; very few (range 0–5%) increased analgesicuse, shifting from no/low analgesic use at baseline tostrong opioid use.Conclusion: Denosumab was associated with clinicallymeaningful improvement in pain outcomes in patientswith GCTB. Pain improvement did not appear to be associatedwith increased analgesic use. Denosumab continuesto be studied as a potential treatment option for patientswith GCTB.Poster #142INDEPENDENT IMAGING ASSESSMENT OFDENOSUMAB TREATMENT FOR GIANT CELLTUMOR OF BONEJean-Yves Blay 1 ; Sant Chawla 2 ; Leanne Seeger 3 ;Robert Henshaw 4 ; Edwin Choy 5 ; Robert Grimer 6 ;Stefano Ferrari 7 ; Peter Reichardt 8 ; Piotr Rutkowski 9 ;Scott Schuetze 10 ; David Thomas 11 ; Antonio Lopez Pousa 12 ;237